Advertisement
News
Advertisement

MediSapiens Launches OncoGenomics Explorer, First-in-Kind Cloud Computing Application for Personalized Genomics

Mon, 09/17/2012 - 8:33am
Bio-Medicine.Org

HELSINKI, Finland and SAN FRANCISCO, September 17, 2012 /PRNewswire/ --

MediSapiens launches first-in-kind fully integrated and unified cloud computing application that harnesses the power of Big Data and enables knowledge-based drug discovery and repositioning for personalized genomics.

This application, called OncoGenomics Explorer, is the next stage of bioinformatics applications for drug discovery. Unlike other cloud computing genomics applications, the Oncogenomics Explorer allows flexible mining of all public and private multi-dimensional biological data available and provides the user with an intuitive and concise visualization and analysis of this vast pool of information. As the first application of its kind, OncoGenomics Explorer also features a revolutionary new search algorithm that allows researchers to perform complex genomics data searches using plain text search phrases. As the result of strict data unification process, OncoGenomics Explorer users will always get straightforward and reliable results to their queries.

The new software was launched today at the Bio-IT World's Cloud Summit in San Francisco by the company's VP of Business Development, Mr. Rami Kakonen.

OncoGenomics Explorer seamlessly integrates multi-dimensional genomics (mutation, methylation, CNV, mRNA) data from a single sample to create a comprehensive genomics tool for scientist fighting to find the cure to cancer.

OncoGenomics Explorer is an ideal tool for the entire pharmaceutical industry. It will significantly lower the drug discovery costs by allowing more accurate target validation and data consolidation. It is also the first web-based omics tool to truly enable personalized genomics because OncoGenomics Explorer allows pharmaceutical scientists to stratify and recruit patients for clinical trials based on their personal genetic signature. This way new therapeutic agents are more often administered to patients who are likely to benefit fr
'/>"/>

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading